Penumbra, Inc.’s (PEN) robust portfolio expansion efforts are poised to help it grow in the upcoming quarters. The company expects impressive growth as it expands globally throughout the rest of 2024 and beyond. A robust solvency position also bodes well for the stock. Meanwhile, macroeconomic volatilities and fiercely competitive space remain a concern for Penumbra.  In the past year, shares of this Zacks Rank #2 (Buy) company have rallied 7.1% compared with the industry’s 14.5% growth and the S&P 500 comp ...

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, particularly in the financial sector, to achieve exceptional returns, although identifying such stocks can be challenging due to their inherent risks and volatility [1] Group 1: Company Overview - Penumbra (PEN) is currently highlighted as a recommended growth stock by the Zacks Growth Style Score system, which evaluates a company's genuine growth prospects beyond traditional metrics [2] - The stock has a favorable Growth Score and a top Zacks Rank, indicating strong potential for performance [2][10] Group 2: Earnings Growth - Earnings growth is a critical factor for investors, with double-digit growth being particularly desirable as it signals strong future prospects [4] - Penumbra has a historical EPS growth rate of 38.8%, with projected EPS growth of 33.6% for the current year, significantly outperforming the industry average of 15.9% [5] Group 3: Cash Flow Growth - High cash flow growth is essential for growth-oriented companies, allowing them to expand without relying on external funding [6] - Penumbra's year-over-year cash flow growth stands at an impressive 255.5%, contrasting sharply with the industry average of -4.9% [6] - The company's annualized cash flow growth rate over the past 3-5 years is 34.6%, compared to the industry average of 5.4% [7] Group 4: Earnings Estimate Revisions - Trends in earnings estimate revisions are indicative of a stock's potential performance, with positive revisions correlating strongly with stock price movements [8] - Penumbra's current-year earnings estimates have been revised upward, with the Zacks Consensus Estimate increasing by 8.2% over the past month [9] Group 5: Investment Potential - The combination of strong earnings estimate revisions and a high Growth Score has positioned Penumbra as a Zacks Rank 2 stock, making it a solid choice for growth investors [10][11]

ALAMEDA, Calif., Nov. 20, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024.Event:     Piper Sandler 36th Annual Healthcare ConferenceDate:      Wednesday, December 4, 2024Time:      8:00am ET/5:00am PTA webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Gro ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style ...

Penumbra, Inc. (PEN) reported third-quarter 2024 adjusted earnings per share (EPS) of 85 cents, which surpassed the Zacks Consensus Estimate by 23.2%. Adjusted EPS improved 26.9% year over year.GAAP earnings were 75 cents per share, a 226% jump from the year-ago GAAP earnings of 23 cents per share.Following the earnings announcement, shares of PEN rose 1.3% in after-market trading yesterday.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q3 Revenues of PENPenumbra registered revenue ...

Penumbra (PEN) reported $301.04 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 11.1%. EPS of $0.85 for the same period compares to $0.67 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $298.09 million, representing a surprise of +0.99%. The company delivered an EPS surprise of +23.19%, with the consensus EPS estimate being $0.69. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wa ...

Penumbra (PEN) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.67 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 23.19%. A quarter ago, it was expected that this medical device maker would post earnings of $0.56 per share when it actually produced earnings of $0.64, delivering a surprise of 14.29%.Over the last four quarters, the com ...

ALAMEDA, Calif., Oct. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2024. Revenue of $301.0 million in the third quarter of 2024, an increase of 11.1% or 10.9% in constant currency1, compared to the third quarter of 2023. U.S. thrombectomy revenue of $162.1 million in the third quarter of 2024 increased 21.2% and 5.4% compared to the third quarter of 2023 and second quarter of 2024, re ...

The latest news from the lab, plus an analyst's bullish move, combined to put some zip in the company's shares. News about one of Penumbra's (PEN 4.02%) development programs and an analyst's price target raise combined to boost the medical device company's stock on Monday. Its price rose by over 4%, giving the stock a clear victory over the S&P 500 index, which increased by 0.8%. Good news from the lab Penumbra announced that it has completed patient enrollment for a clinical trial to evaluate its Penumbra ...